Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 128

1.

Safety of clopidogrel being continued until the time of coronary artery bypass grafting in patients with acute coronary syndrome: a meta-analysis of 34 studies.

Nijjer SS, Watson G, Athanasiou T, Malik IS.

Eur Heart J. 2011 Dec;32(23):2970-88. doi: 10.1093/eurheartj/ehr151. Epub 2011 May 24.

PMID:
21609973
2.

Impact of clopidogrel in patients with acute coronary syndromes requiring coronary artery bypass surgery: a multicenter analysis.

Berger JS, Frye CB, Harshaw Q, Edwards FH, Steinhubl SR, Becker RC.

J Am Coll Cardiol. 2008 Nov 18;52(21):1693-701. doi: 10.1016/j.jacc.2008.08.031.

3.

Outcomes following pre-operative clopidogrel administration in patients with acute coronary syndromes undergoing coronary artery bypass surgery: the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial.

Ebrahimi R, Dyke C, Mehran R, Manoukian SV, Feit F, Cox DA, Gersh BJ, Ohman EM, White HD, Moses JW, Ware JH, Lincoff AM, Stone GW.

J Am Coll Cardiol. 2009 May 26;53(21):1965-72. doi: 10.1016/j.jacc.2009.03.006.

4.

Combined clopidogrel and aspirin treatment up to surgery increases the risk of postoperative myocardial infarction, blood loss and reoperation for bleeding in patients undergoing coronary artery bypass grafting.

Miceli A, Duggan SM, Aresu G, de Siena PM, Romeo F, Glauber M, Caputo M, Angelini GD.

Eur J Cardiothorac Surg. 2013 Apr;43(4):722-8. doi: 10.1093/ejcts/ezs369. Epub 2012 Jun 24.

PMID:
22733842
5.

Dual antiplatelet therapy in patients requiring urgent coronary artery bypass grafting surgery: a position statement of the Canadian Cardiovascular Society.

Fitchett D, Eikelboom J, Fremes S, Mazer D, Singh S, Bittira B, Brister S, Graham J, Gupta M, Karkouti K, Lee A, Love M, McArthur R, Peterson M, Verma S, Yau T.

Can J Cardiol. 2009 Dec;25(12):683-9. English, French.

6.

Should clopidogrel be discontinued before coronary artery bypass grafting for patients with acute coronary syndrome? A systematic review and meta-analysis.

Cao C, Indraratna P, Ang SC, Manganas C, Park J, Bannon PG, Yan TD.

J Thorac Cardiovasc Surg. 2014 Dec;148(6):3092-8. doi: 10.1016/j.jtcvs.2014.04.054. Epub 2014 May 23. Review.

7.

Benefits and risks of using clopidogrel before coronary artery bypass surgery: systematic review and meta-analysis of randomized trials and observational studies.

Biancari F, Airaksinen KE, Lip GY.

J Thorac Cardiovasc Surg. 2012 Mar;143(3):665-675.e4. doi: 10.1016/j.jtcvs.2011.01.069. Epub 2011 Jun 24. Review.

8.

Coronary artery bypass graft surgery in acute coronary syndrome: incidence, cost impact, and acute clopidogrel interruption.

Johnston SS, Bell K, Gdovin J, Jing Y, Graham J.

Hosp Pract (1995). 2012 Feb;40(1):15-23. doi: 10.3810/hp.2012.02.944.

PMID:
22406879
9.

Impact of clopidogrel and potent P2Y 12 -inhibitors on mortality and stroke in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: a systematic review and meta-analysis.

Aradi D, Komócsi A, Vorobcsuk A, Serebruany VL.

Thromb Haemost. 2013 Jan;109(1):93-101. doi: 10.1160/TH12-06-0377. Epub 2012 Nov 29. Review.

PMID:
23197191
10.

Acute clopidogrel use and outcomes in patients with non-ST-segment elevation acute coronary syndromes undergoing coronary artery bypass surgery.

Mehta RH, Roe MT, Mulgund J, Ohman EM, Cannon CP, Gibler WB, Pollack CV Jr, Smith SC Jr, Ferguson TB, Peterson ED.

J Am Coll Cardiol. 2006 Jul 18;48(2):281-6. Epub 2006 Jun 21.

11.

Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: Data from the PLATO Trial.

Patel MR, Becker RC, Wojdyla DM, Emanuelsson H, Hiatt WR, Horrow J, Husted S, Mahaffey KW, Steg PG, Storey RF, Wallentin L, James SK.

Eur J Prev Cardiol. 2015 Jun;22(6):734-42. doi: 10.1177/2047487314533215. Epub 2014 May 15.

PMID:
24830710
12.

Coronary artery bypass grafting-related bleeding complications in patients treated with ticagrelor or clopidogrel: a nationwide study.

Hansson EC, Jidéus L, Åberg B, Bjursten H, Dreifaldt M, Holmgren A, Ivert T, Nozohoor S, Barbu M, Svedjeholm R, Jeppsson A.

Eur Heart J. 2016 Jan 7;37(2):189-97. doi: 10.1093/eurheartj/ehv381. Epub 2015 Sep 1.

13.

Does clopidogrel increase blood loss following coronary artery bypass surgery?

Chu MW, Wilson SR, Novick RJ, Stitt LW, Quantz MA.

Ann Thorac Surg. 2004 Nov;78(5):1536-41.

PMID:
15511426
14.

Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis.

Smith PK, Goodnough LT, Levy JH, Poston RS, Short MA, Weerakkody GJ, Lenarz LA.

J Am Coll Cardiol. 2012 Jul 31;60(5):388-96. doi: 10.1016/j.jacc.2012.03.030. Epub 2012 May 23.

16.

Clopidogrel does not increase bleeding and allogenic blood transfusion in coronary artery surgery.

Karabulut H, Toraman F, Evrenkaya S, Goksel O, Tarcan S, Alhan C.

Eur J Cardiothorac Surg. 2004 Mar;25(3):419-23.

PMID:
15019671
17.

Antiplatelet therapy at the time of coronary artery bypass grafting: a multicentre cohort study.

Kremke M, Tang M, Bak M, Kristensen KL, Hindsholm K, Andreasen JJ, Hjortdal V, Jakobsen CJ.

Eur J Cardiothorac Surg. 2013 Aug;44(2):e133-40. doi: 10.1093/ejcts/ezt230. Epub 2013 May 9.

PMID:
23660554
18.

Patients with non-ST-elevation acute coronary syndromes undergoing coronary artery bypass grafting in the modern era of antithrombotic therapy.

Chew DP, Huang Z, Pieper KS, White H, Mahaffey KW, Ferguson JJ, Califf RM, Aylward PG.

Am Heart J. 2008 Feb;155(2):239-44. doi: 10.1016/j.ahj.2007.10.002. Epub 2007 Nov 26.

PMID:
18215592
19.

Coronary artery bypass grafting-related bleeding complications in real-life acute coronary syndrome patients treated with clopidogrel or ticagrelor.

Hansson EC, Rexius H, Dellborg M, Albertsson P, Jeppsson A.

Eur J Cardiothorac Surg. 2014 Oct;46(4):699-705; discussion 705. doi: 10.1093/ejcts/ezt662. Epub 2014 Jan 30.

PMID:
24482383
20.

Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial.

Becker RC, Bassand JP, Budaj A, Wojdyla DM, James SK, Cornel JH, French J, Held C, Horrow J, Husted S, Lopez-Sendon J, Lassila R, Mahaffey KW, Storey RF, Harrington RA, Wallentin L.

Eur Heart J. 2011 Dec;32(23):2933-44. doi: 10.1093/eurheartj/ehr422. Epub 2011 Nov 16. Erratum in: Eur Heart J. 2012 Nov;33(21):2750.

PMID:
22090660

Supplemental Content

Support Center